Cite

HARVARD Citation

    Stone, J. et al. (n.d.). Was there really any evidence that rosiglitazone increased the risk of myocardial infarction or death from cardiovascular causes?. Pharmacoepidemiology and drug safety. pp. 223-227. [Online]. 
  
Back to record